MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,765.36
-0.47%
NASDAQ 100
$30,725.81
-1.39%
DOW JONES
$51,232.00
+0.10%
NASDAQ Composite
$27,193.34
-1.25%
RUSSELL 2000
$2,775.70
-0.05%
CBOE VIX
$15.41
+2.19%
Sector Heatmap
Technology-1.79%
Financials+0.89%
Healthcare-0.39%
Consumer Cycl+0.31%
Consumer Staples+2.11%
Energy+2.97%
Industrials+0.33%
Materials+0.59%
Real Estate+0.69%
Utilities-0.19%
Comm Services+0.73%
SLS — SELLAS Life Sciences Group, Inc. Common Stock
NasdaqSELLAS Life Sciences Group, Inc. Common Stock
$11.26
-0.05(-0.44%)
- O
- 11.17
- H
- 11.34
- L
- 10.71
- V
- 4.18M
⏱️ End-of-day dataAs of Oct 8, 2026
Chart
About SLS
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMar 12, 2008
Employees13
Stock ExchangeNasdaq
Ticker SymbolSLS
Key Financial Statistics
| Market Cap | $2.37B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.39 - $15.88 |
| 52-Week Avg Volume | 7.50M |
| VWAP | $11.03 |
| Transactions | 29,355 |
| Total Recorded Bars | 4,674 days |